GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Asset Turnover

GALT (Galectin Therapeutics) Asset Turnover : 0.00 (As of Sep. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Galectin Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Galectin Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Galectin Therapeutics's Total Assets for the quarter that ended in Sep. 2024 was $28.31 Mil. Therefore, Galectin Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Galectin Therapeutics's annualized ROE % for the quarter that ended in Sep. 2024 was 51.40%. It is also linked to ROA % through Du Pont Formula. Galectin Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 was -158.51%.


Galectin Therapeutics Asset Turnover Historical Data

The historical data trend for Galectin Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Asset Turnover Chart

Galectin Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Galectin Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Galectin Therapeutics's Asset Turnover

For the Biotechnology subindustry, Galectin Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Asset Turnover falls into.



Galectin Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Galectin Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (21.285+28.2)/ 2 )
=0/24.7425
=0.00

Galectin Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (27.655+28.972)/ 2 )
=0/28.3135
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Galectin Therapeutics  (NAS:GALT) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Galectin Therapeutics's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-44.88/-87.314
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-44.88 / 0)*(0 / 28.3135)*(28.3135/ -87.314)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.3243
=ROA %*Equity Multiplier
=-158.51 %*-0.3243
=51.40 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Galectin Therapeutics's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-44.88/28.3135
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-44.88 / 0)*(0 / 28.3135)
=Net Margin %*Asset Turnover
= %*0
=-158.51 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Galectin Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Galectin Therapeutics Business Description

Traded in Other Exchanges
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Executives
Kary Eldred director 2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman director 712 LAKEWAY DRIVE, KELLER TX 76248
Zordani Richard A. Jr. director 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
Joel Lewis director 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
James C Czirr director 4908 SOUTH ASHTON COURT, SPOKANE WA 99223
10x Fund, L.p. 10 percent owner 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz director 235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio director 5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein director, 10 percent owner 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes officer: Chief Medical Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Harold H. Shlevin director, officer: Chief Executive Officer C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Jack W Callicutt officer: Chief Financial Officer 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
Peter G Traber director, officer: President and CEO 430 THAMER LANE, HOUSTON TX 77025

Galectin Therapeutics Headlines

From GuruFocus